UK startup NodThera banks a $40M round with plans to conquer a closely-studied inflammatory target
A startup in Cambridge, UK called NodThera has banked a $40 million A round to dig deeper into developing small molecules targeting NLRP3, a rather notorious inflammasome that’s been linked to a variety of inflammatory conditions.
CEO Alan Watt explains that he was researching this target a decade ago when he worked at GlaxoSmithKline in a senior research position. “At that point,” he says, “we didn’t find any chemical leads.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.